Roivant Sciences Ltd. (ROIV)
10.89
0.15 (1.40%)
At close: Apr 24, 2025, 12:17 PM
Company Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.
The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
The company was founded in 2014 and is based in London, the United Kingdom.
Roivant Sciences Ltd.
| Country | GB |
| IPO Date | Dec 8, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 908 |
| CEO | Matthew Gline |
Contact Details
Address: 11-12 St. James's Square London, GB | |
| Website | https://roivant.com |
Stock Details
| Ticker Symbol | ROIV |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001635088 |
| CUSIP Number | G76279101 |
| ISIN Number | BMG762791017 |
| Employer ID | 98-1173944 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Gline | Chief Executive Officer & Director |
| Dr. Eric Venker M.D., Pharm.D. | President & Chief Operating Officer |
| Dr. Matt Maisak | Chief Operating Officer of Roivant Platforms |
| Drew Kramer | Chief Information Officer |
| Richard Pulik | Chief Financial Officer |
| Alex Gasner | Executive Vice President of Roivant Health |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director |
| Dr. Srini Ramanathan Ph.D. | Chief Development Officer |
| Josh Chen J.D. | General Counsel |
| Kelly Graff | Head of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | 4 | Filing |
| Apr 22, 2025 | 4 | Filing |
| Apr 22, 2025 | 4 | Filing |
| Apr 21, 2025 | 4 | Filing |
| Apr 21, 2025 | 4 | Filing |
| Apr 21, 2025 | 4 | Filing |
| Apr 21, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 21, 2025 | 8-K | Current Report |
| Apr 01, 2025 | 4 | Filing |
| Mar 24, 2025 | 4 | Filing |